← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)
Hebei Senlang Biotechnology Inc., …·CD19
8 trials
Overview
Program
Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Overview
Company
Hebei Senlang Biotechnology Inc., Ltd.
Overview
Modality
CGT
Overview
Target
CD19
Overview
Indication
19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Mechanism
targeting multiple tumor antigen
PK/PD
Experiment
PD
Toxicology
Major finding
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.. Burkitt lymphoma (BL) is one of the most frequent subtypes of non-Hodgkin lymphoma (NHL) in children. Currently, short, intensive chemotherapy is used internationally and has greatly improved survival in children…
Toxicology
CRS
Reported
Clinical
Safety signal
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.. Burkitt lymphoma (BL) is one of the most frequent subtypes of non-Hodgkin lymphoma (NHL) in children. Currently, short, intensive chemotherapy is used internationally and has greatly improved survival in children…
Clinical
Program phase
PHASE_1